Study: Azacitidine extends survival for pre-leukemia patients

02/18/2009 | Yahoo!

Patients with myelodysplastic syndrome who were injected with azacitidine for six months survived more than nine months longer than those who underwent conventional treatment. The results indicate that the drug "should become the reference treatment" in most patients with the bone marrow disorder, researchers said.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations